The October 5 webcast is the key catalyst. Investors should watch for immunogenicity non-inferiority vs Prevnar 20 and safety profile. The stock will likely gap significantly on the data release — position accordingly before the event.
Price Chart
Executive Summary
Vaxcyte announced it will host a webcast on October 5, 2026 to present topline Phase 3 data from the OPUS-1 trial of VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. This is a binary catalyst event — positive data could transform the company's valuation as VAX-31 is the broadest-spectrum PCV in the clinic, while negative data would be a major setback for a clinical-stage company with no approved products.
Key Facts
- Topline data from the OPUS-1 adult pivotal Phase 3 trial of VAX-31 will be presented on October 5, 2026 at 8:00 a.m. ET.
- VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease and pneumococcal pneumonia.
- Vaxcyte is a clinical-stage company with no approved products — VAX-31 is its lead candidate.
- The company also has VAX-24 (24-valent PCV, positive Phase 2 results in adults and infants), VAX-XL (earlier-stage), VAX-A1 (Group A Strep, Phase 1), and VAX-GI (Shigella, preclinical).
Financial Impact
Binary catalyst — positive Phase 3 data could drive substantial upside (8-15%+ CAR typical for early-stage biotech approvals); negative data would be severely bearish (20-50%+ decline likely for single-asset company). No financial figures provided in the release.
Risk Factors
- Phase 3 data may fail to meet non-inferiority endpoints vs standard-of-care PCVs.
- Safety signals could emerge that delay or prevent approval.
- As a clinical-stage company with no approved products, a negative readout would severely impair the stock.
- Manufacturing or CMC issues could arise despite positive efficacy data.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $70.65 $63.68 | ▲ +9.87% | ▲ +8.37% | $60.67 (+14.13%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 8, 2026 19d ago | 424B5 | $71.38 $63.62 | ▲ +10.87% | ▲ +8.90% | $60.67 (+15.00%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▲ +0.15% | ▲ +0.29% | $60.67 (−9.04%) |
Oct 5, 2026 22d ago | 424B5 | $66.70 $66.80 | ▼ −0.15% | ▼ −0.29% | $60.67 (+9.04%) |
Oct 5, 2026 22d ago | 8-K | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 5, 2026 22d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Oct 4, 2026 23d ago | Press Release | $73.82 $70.65 | ▼ −4.29% | ▼ −4.72% | $60.67 (−17.81%) |
Aug 5, 2026 11w ago | Insider Cluster | $58.89 $58.86 | ▼ −0.05% | ▼ −1.26% | $60.67 (+3.02%) |
Jul 6, 2026 16w ago | Insider Cluster | $60.67 $56.21 | ▼ −7.35% | ▼ −7.90% | $60.67 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers